Merck KGaA
MRK: XETR (DEU)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| T^y | LOCK|%B?> | LOCK|nxjl>GT |
Merck KGaA: SpringWorks Acquisition Strengthens Healthcare Portfolio; Shares Undervalued
Merck KGaA announced the acquisition of US biotech firm SpringWorks Therapeutics at an approximate enterprise value of EUR 3 billion. The transaction will be funded through a combination of cash and newly funded debt.
